advertisement

Topcon

Omodaka K 34

Showing records 1 to 25 | Display all abstracts from Omodaka K

84822 Evaluation of Papillomacular Nerve Fiber Bundle Thickness in Glaucoma Patients with Visual Acuity Disturbance
Takahashi N
Current Eye Research 2019; 0: 1-7
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Sato K
Current Eye Research 2020; 0: 1-10
84975 The association between oxidative stress and corneal hysteresis in patients with glaucoma
Uchida K
Scientific reports 2020; 10: 545
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Yamamoto K
Scientific reports 2019; 9: 19288
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Yabana T
PLoS ONE 2019; 14: e0227078
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Nakagawa Y
Current Eye Research 2020; 0: 1-10
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Kokubun T
Scientific reports 2019; 9: 19288
84975 The association between oxidative stress and corneal hysteresis in patients with glaucoma
Himori N
Scientific reports 2020; 10: 545
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Sato K
PLoS ONE 2019; 14: e0227078
84822 Evaluation of Papillomacular Nerve Fiber Bundle Thickness in Glaucoma Patients with Visual Acuity Disturbance
Omodaka K
Current Eye Research 2019; 0: 1-7
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Shiga Y
PLoS ONE 2019; 14: e0227078
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Sato K
Scientific reports 2019; 9: 19288
84975 The association between oxidative stress and corneal hysteresis in patients with glaucoma
Hashimoto K
Scientific reports 2020; 10: 545
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Omodaka K
Current Eye Research 2020; 0: 1-10
84822 Evaluation of Papillomacular Nerve Fiber Bundle Thickness in Glaucoma Patients with Visual Acuity Disturbance
Pak K
Current Eye Research 2019; 0: 1-7
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Asada H
Current Eye Research 2020; 0: 1-10
84822 Evaluation of Papillomacular Nerve Fiber Bundle Thickness in Glaucoma Patients with Visual Acuity Disturbance
Kikawa T
Current Eye Research 2019; 0: 1-7
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Akaishi T
Scientific reports 2019; 9: 19288
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Himori N
PLoS ONE 2019; 14: e0227078
84975 The association between oxidative stress and corneal hysteresis in patients with glaucoma
Shiga Y
Scientific reports 2020; 10: 545
84822 Evaluation of Papillomacular Nerve Fiber Bundle Thickness in Glaucoma Patients with Visual Acuity Disturbance
Kobayashi W
Current Eye Research 2019; 0: 1-7
84839 The relationship between glutathione levels in leukocytes and ocular clinical parameters in glaucoma
Omodaka K
PLoS ONE 2019; 14: e0227078
84975 The association between oxidative stress and corneal hysteresis in patients with glaucoma
Tsuda S
Scientific reports 2020; 10: 545
84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Shimazaki A
Scientific reports 2019; 9: 19288
85049 The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats
Fujii S
Current Eye Research 2020; 0: 1-10

Issue 21-1

Change Issue


advertisement

Oculus